Variant · Other
KEAP1 Mutation
CI-VAR-00002827Explore in graph →CIViC 5116
Curated evidence
Evidence by cancer (5 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 39385035
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma5 | ||||||||
| KEAP1 Mutation | Chemotherapy + Durvalumab Regimen + TremelimumabCombination | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID12419The POSEIDON (NCT03164616) open-label, randomized phase 3 trial included 1,013 patients with metastatic non-small-cell lung cancer (NSCLC), of whom 637 had nonsquamous histology and 612 were evaluable… (full text at CIViC) PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC | civic |
| KEAP1 Mutation | Cisplatin/Pembrolizumab/Pemetrexed Regimen | Predictive | B | Supports Resistance | 4 | submitted | EID12339A retrospective analysis of 871 non-squamous NSCLC patients treated with chemotherapy (platinum compound plus pemetrexed) combined with immunotherapy (pembrolizumab) found that those with KEAP1 mutati… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available